Denali Therapeutics Inc (DNLI) - News Archive

Denali Therapeutics’ Recent Announcements: Key Facts and Implications Denali Therapeutics Inc., a cutting-edge biopharmaceutical company, is making significant strides in addressing complex and rare diseases through inn...

Denali Therapeutics Sets Ambitious 2025 Milestones Despite Financial StrugglesDenali Therapeutics Inc. a biotech firm focused on developing therapies for neurodegeneration and lysosomal storage diseases, recently outlin...

Denali Therapeutics Inc. has recently announced a successful meeting with the U.S. Food and Drug Administration (FDA) concerning its investigational therapeutic, Tividenofusp Alfa (DNL310), aimed at treating Mucopolysac...

In the venerable realm of biopharmaceutical innovation, the illustrious Denali Therapeutics Inc., headquartered in the charming enclave of South San Francisco, has recently revealed a monumental stride in medical scienc...

Denali Therapeutics Inc., a leading biopharmaceutical company committed to developing innovative treatment options for neurodegenerative and lysosomal storage diseases, has announced the successful completion of enrollm...

:Denali Therapeutics, a renowned biopharmaceutical company, recently announced its expansion and promising new data regarding its work on enzyme replacement therapies (ERTs) engineered to traverse the blood-brain barrie...

At the start of the new year, Denali Therapeutics Inc., a biopharmaceutical company operating from South San Francisco, California, has revealed key resolutions and goals for the year 2024. This announcement comes just...